Skip to main content
. 2016 Jun 11;7(29):45764–45775. doi: 10.18632/oncotarget.9945

Table 3. Clinical characteristics of discovery cohort.

Characteristic Patients (N=36)
Sex
 Male 23 (63.9 %)
 Female 13 (36.1 %)
 Median Age [y] 59 (34-78)
Age Category
 < 50 y 13 (36.1 %)
 ≥ 50 y 23 (63.9 %)
MGMT promoter methylation status
 Methylated 18 (50.0 %)
 Unmethylated 18 (50.0 %)
Secondary Malignisation
 Yes 12 (33.3 %)
 No 24 (66.7 %)
Concomitant Temozolomide
 Yes 32 (88.9 %)
 No 1 (2.8 %)
 Unknown 3 (8.3 %)
Median adjuvant TMZ cycles 6 (0−20)